News
following the encouraging clinical activity and tolerability seen in the WTX-330x2101 first-in-human study. Werewolf’s previously announced development candidates WTX-712, its Interleukin-21 (IL ...
following the encouraging clinical activity and tolerability seen in the WTX-330x2101 first-in-human study. Werewolf’s previously announced development candidates WTX-712, its Interleukin-21 (IL ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback